In particular, IGF-1R was considered as a promising drug target for CRC therapy [4], and the specific IGF-1R inhibitor picropodophyllin (PPP, or AXL1717) strongly inhibited the proliferation and migration of multiple CRC cell lines in a dose-dependent manner [5]. Here, IGF1R is linked to colorectal carcinoma.